Today: 17 March 2026
Subscribe
Browse Category

ASX:ARB 2 December 2025 - 24 February 2026

ARB share price dives 13% after profit slides; ASX:ARB outlook and April dividend in focus

ARB share price dives 13% after profit slides; ASX:ARB outlook and April dividend in focus

ARB shares dropped 13.1% to A$21.36 after first-half profit before tax fell 18.8% to A$57.1 million and revenue slipped 1% to A$358 million. The company blamed weaker sales margins on currency and factory cost pressures. Interim dividend was held at 34 cents a share, with a record date of April 2. ARB reported cash of A$59.4 million and no debt at December 31.
24 February 2026
··
ARB Corporation Limited (ASX:ARB) Share Price, Latest Announcements and 2026 Outlook – 4 December 2025

ARB Corporation Limited (ASX:ARB) Share Price, Latest Announcements and 2026 Outlook – 4 December 2025

ARB Corporation shares traded at $32.8–$33.0 on December 4, 2025, near the lower half of their 52-week range. The company lifted CEO Lachlan McCann’s fixed pay to about $1.39 million, effective October 1. ARB also announced the proposed issue of 22,739 performance rights to senior executives, representing potential dilution of about 0.03%.
4 December 2025
··
ARB Corporation Limited (ASX:ARB) Share Price, ASX Announcements and Analyst Forecasts – 2 December 2025

ARB Corporation Limited (ASX:ARB) Share Price, ASX Announcements and Analyst Forecasts – 2 December 2025

ARB Corporation shares fell about 2–2.5% to A$32.70 on 2 December, extending a 9% slide since early November and leaving the stock down 23% over 12 months. The company lodged a notice for a proposed issue of 22,739 performance rights, while investors also weighed CEO pay changes and a shift in substantial shareholding. Market cap stands near A$2.8 billion.
2 December 2025
···

Stock Market Today

  • Agenus Q4 Earnings Exceed Estimates with $0.56 EPS and $34.2M Revenue
    March 16, 2026, 10:29 PM EDT. Agenus (AGEN) reported a quarterly earnings per share (EPS) of $0.56, significantly beating the Zacks Consensus Estimate loss of $1.27 and the previous year's $2.04 loss. This marked an earnings surprise of +144.27%. The biotechnology firm also posted revenues of $34.2 million, surpassing estimates by 17.54% and up from $26.84 million a year ago. Despite positive earnings and revenue surprises, Agenus stock has declined about 1.3% year-to-date, trailing the S&P 500's 3.1% drop. The company holds a Zacks Rank #3 (Hold), projecting in-line market performance ahead. Investors await management's commentary on the earnings call and future estimate revisions amid mixed consensus for upcoming quarters.
Go toTop